Hyperphosphatemia
📧 Sign up to get email alerts when something new happens for Hyperphosphatemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis [Phase 3]
Phase 3 clinical trial TS-172 for hyperphosphatemia in patients on hemodialysis is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis [Phase 3]
This is a Phase 3 clinical trial evaluating TS-172 for hyperphosphatemia in patients on peritoneal dialysis; the study is not yet recruiting…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders [Phase 3]
Clinical trial update announcing a Phase 3 study of TS-172 for hyperphosphatemia in patients on hemodialysis, currently recruiting.
-
EMA approval · 2026-03-24EMA Authorised: Velphoro (sucroferric oxyhydroxide) — Vifor Fresenius Medical Care Renal Pharma France
The EMA authorized Velphoro (sucroferric oxyhydroxide) for the treatment of hyperphosphatemia in patients with chronic kidney disease on ren…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China [Phase 3]
A Phase 3 clinical trial update for AP301, an iron-based phosphate binder, evaluating its use for hyperphosphatemia in patients with chronic…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis [Phase 3]
A Phase 3 long-term study of TS-172 for hyperphosphatemia in patients on hemodialysis is currently recruiting. The trial aims to evaluate sa…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia [Phase 3]
Phase 3 trial of AP301 for hyperphosphatemia in Chinese dialysis patients has completed.
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis [Phase 3]
This update reports the completion of a Phase 3 study evaluating TS-172 for treating hyperphosphatemia in patients on hemodialysis.
-
EMA approval · 2025-11-06EMA Authorised: Xoanacyl (ferric citrate coordination complex) — Averoa
EMA authorised Xoanacyl, a ferric citrate coordination complex, for the treatment of iron deficiency and to manage hyperphosphatemia in chro…
-
FDA approval · 2025-10-27FDA Approved: SEVELAMER CARBONATE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved sevelamer carbonate (generic) from Zydus Pharmaceuticals USA Inc. as an original application. The approval covers treatment of …
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Phosphate Diet Strategies to Lower Blood Phosphate in Dialysis Patients [NA]
A completed clinical trial evaluating dietary phosphate reduction strategies to lower serum phosphate in dialysis patients with hyperphospha…
-
CLINICAL_TRIALS trial_result · 2025-08-29Clinical Trial Update: Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease [Phase 3]
Phase 3 trial update on ferric citrate for the prevention of renal failure in adults with advanced chronic kidney disease; trial has complet…
-
CLINICAL_TRIALS trial_result · 2025-08-07Clinical Trial Update: A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders [Phase 2]
Phase 2 trial of TS-172 for hyperphosphatemia in patients on hemodialysis has completed.
-
CLINICAL_TRIALS research · 2025-07-01Clinical Trial Update: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE) [NA]
A pragmatic randomized trial comparing high versus standard phosphate targets in adults with end-stage renal disease and hyperphosphatemia. …
-
FDA approval · 2025-03-10FDA Approved: SEVELAMER CARBONATE — Supplemental Application (DR. REDDY'S LABORATORIES LIMITED)
FDA approves a supplemental application for sevelamer carbonate filed by Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis [Phase 2]
Phase 2 dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis has completed.
-
CLINICAL_TRIALS research · 2025-02-14Clinical Trial Update: Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism
This clinical trials entry describes the plan to establish an Italian multicenter database for patients with phosphate metabolism disorders,…
-
FDA approval · 2025-02-03FDA Approved: SEVELAMER HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approves the original application for sevelamer hydrochloride (generic) by Zydus Pharmaceuticals USA Inc. for the treatment of hyperphos…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of JMKX003002 in end-stage renal disease patients on hemodialysis with hyperp…
-
FDA approval · 2025-01-31FDA Approved: LANTHANUM CARBONATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for Lanthanum carbonate from Cipla USA Inc., approving an update to the product's labeling for the g…
-
EMA approval · 2025-01-22EMA Authorised: Renagel (sevelamer) — Sanofi Winthrop Industrie
The EMA authorised Renagel (sevelamer) for hyperphosphatemia in patients with chronic kidney disease on dialysis, with Sanofi Winthrop Indus…
-
EMA approval · 2025-01-08EMA Authorised: Renvela (sevelamer carbonate) — Sanofi Winthrop Industrie
The EMA authorized Renvela (sevelamer carbonate) for the treatment of hyperphosphatemia in patients on renal dialysis, under Sanofi Winthrop…
-
EMA approval · 2024-12-18EMA Authorised: Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva) (sevelamer carbonate) — Sanofi Winthrop Industrie
EMA has authorised Sevelamer carbonate Winthrop for treating hyperphosphatemia in patients on renal dialysis (formerly Zentiva), with Sanofi…
-
FDA approval · 2024-12-11FDA Approved: LANTHANUM CARBONATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for lanthanum carbonate from Teva Pharmaceuticals USA, Inc. This action is a supplemental approval f…
-
CLINICAL_TRIALS trial_result · 2024-12-02Clinical Trial Update: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia [Phase 2]
Phase 2 study evaluating AP306 at fixed doses for safety, tolerability, and efficacy in hyperphosphatemia associated with chronic kidney dis…